Skip to main content

Zalcitabine Pregnancy and Breastfeeding Warnings

Brand names: Hivid

Zalcitabine Pregnancy Warnings

Zalcitabine has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of embryolethality and teratogenicity at high doses. There are no controlled data in human pregnancy. Zalcitabine should only be given during pregnancy when there are no alternatives and benefit outweighs risk.

An Antiretroviral Pregnancy Registry has been established to monitor maternal:fetal outcomes of zalcitabine exposures during pregnancy. To register patients, physicians should call 800-526-6367.

See references

Zalcitabine Breastfeeding Warnings

There are no data on the excretion of zalcitabine into human milk. HIV-infected mothers should not breast-feed their infants due to the risk of transmission of HIV via breast milk.

See references

References for pregnancy information

  1. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories
  2. Briggs GG, Freeman RK, Yaffe SJ.. (1998) "Drugs in Pregnancy and Lactation." Baltimore, MD: Williams & Wilkins
  3. Perinatal HIV Guidelines Working Group (2008) Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/Perinata

References for breastfeeding information

  1. Fairbrothers D, Kirby E, Lester RM, Wegmann PC, Marshall F, Parkin WE (1985) "Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and AIDS." MMWR Morb Mortal Wkly Rep, 34, p. 721-34
  2. Newell ML, Dunn D, Peckham CS, Ades AE, Pardi G, Semprini AE (1992) "Risk factors for mother-to-child transmission of HIV-1." Lancet, 339, p. 1007-12
  3. (2001) "Product Information. HIVID (zalcitabine)." Roche Laboratories
  4. Perinatal HIV Guidelines Working Group, Public Health Service Task Force (2005) Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. http://aidsinfo.nih.gov/guidelines/perinatal/PER_121704.pdf

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer